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Abstract
Objective. To evaluate the durability of improve-
ment and long-term efficacy of milnacipran treat-
ment in fibromyalgia, to assess efficacy in patients
re-randomized from placebo to milnacipran, and to
collect additional information on the tolerability and
efficacy of long-term treatment with milnacipran.
Design. A total of 449 patients who successfully
completed a 6-month lead-in study enrolled in
this 6-month extension study (87.7% of eligible sub-
jects). Patients initially receiving milnacipran
200 mg/day during the lead-in study were main-
tained at 200 mg/day (n = 209); patients initially
assigned to placebo or milnacipran 100 mg/day
were re-randomized (1:4) to either 100 mg/day
(n = 48) or 200 mg/day (n = 192) of milnacipran for an
additional 6 months of treatment. Efficacy assess-
ments included visual analog scale pain ratings,
Fibromyalgia Impact Questionnaire (FIQ) total score,
and Patient Global Impression of Change (PGIC).
Results. Patients continuing on milnacipran dem-
onstrated a sustained reduction in pain over the
full 12-month period. Additional beneficial effects
were also maintained, as indicated by the PGIC and
FIQ. Patients initially assigned to either placebo or
milnacipran 100 mg/day in the lead-in study and
subsequently re-randomized to milnacipran 200 mg/
day in the extension study experienced further
improvements in their mean pain scores, FIQ total
scores, and PGIC ratings at 1 year. Milnacipran treat-
ment was generally well tolerated. The most com-
monly reported newly emergent adverse event was
nausea.
Conclusions. In addition to confirming that mil-
nacipran safely and effectively improves the mul-
tiple symptoms of fibromyalgia, these data indicate
that milnacipran provides 1-year durable efficacy in
this patient population.
Key Words. Fibromyalgia; Milnacipran; Serotonin-
Norepinephrine Reuptake Inhibitor; Pain; Analgesic;
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Introduction
Fibromyalgia (FM) is a chronic pain disorder affecting
2–4% of the population and is more common in women
than in men [1,2]. Recent biologic and neuroimaging
studies support the hypothesis that aberrant pain pro-
cessing in the central nervous system of FM patients may
represent an important underlying defect [3,4]. In 1990,
the American College of Rheumatology (ACR) established
diagnostic criteria for FM, primarily to standardize clinical
trial populations [5]. These criteria require an individual to
possess chronic widespread pain involving all four quad-
rants of the body and axial skeleton in combination with
tenderness in 11 of 18 standardized “tender points” on
palpation. While the cardinal symptom of FM is chronic
widespread pain, fatigue, sleep and cognitive distur-
bances, and decreased physical function also constitute
important clinical domains of FM [5,6].
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The symptoms associated with FM contribute to a signifi-
cantly reduced quality of life and increased disability and
health care costs [7–9]. Therefore, effective long-term
treatment options with durable clinical benefits are impor-
tant for treating FM patients. Although FM is considered a
chronic, persistent illness, most published pharmaco-
therapy studies have focused on short-term (<3 months)
results. However, long-term clinical trials are necessary to
determine whether the efficacy and safety of a drug docu-
mented in short-term studies are maintained over longer
periods of time [10].
Tricyclic antidepressants were the first medications found
to be beneficial in FM during randomized clinical trials.
Most of these trials were 6–12 weeks in duration and
when carried out to 6 months, significant improvements
over placebo were not observed [11]. Selective serotonin
reuptake inhibitors have shown limited efficacy in FM trials
[10,11]. Pregabalin, an antiseizure medication, was the
first drug approved by the U.S. Food and Drug Adminis-
tration (FDA) for the management of FM. Trials involving
either pregabalin or gabapentin in treating FM have lasted
from 2 to 6 months [12–16]. Duloxetine, a dual reuptake
inhibitor of serotonin and norepinephrine, is also approved
by the FDA for the management of FM. The efficacy and
safety of duloxetine in FM patients has been investigated
in clinical trials lasting 3 months [17,18] and 6 months
[19,20], with 6-month extension studies [21] conducted
on the two 6-month trials.
Milnacipran was approved by the U.S. FDA in January
2009 for the management of FM. It is a dual reuptake
inhibitor of norepinephrine and serotonin that differs from
other medications in this class by having low protein
binding, minimal hepatic metabolism, and no significant
effect on cytochrome P450 enzymes, indicating a low
potential for pharmacokinetic drug interactions [22]. Addi-
tionally, milnacipran differs from other dual reuptake inhibi-
tors by its approximate 3:1 preference for norepinephrine
reuptake inhibition over that of serotonin [23]. Research
suggests that norepinephrine and serotonin are among
several neurotransmitter systems that may mediate
endogenous analgesic mechanisms in the central nervous
system [24,25]. It has also been postulated that norepi-
nephrine reuptake inhibition may be more important than
serotonin for the treatment of pain-related conditions
[26–28]. However, the degree of NE to 5-HT reuptake
inhibition may or may not be related to clinical efficacy.
The efficacy and safety of milnacipran has been previously
established in three double-blind, placebo-controlled
studies of 3 [29,30] and 6 months [31] in duration. Studies
showed that compared with placebo, milnacipran signifi-
cantly improved pain and multiple other symptoms of FM
simultaneously, using a composite responder analysis
[29,31]. These studies also demonstrated significant
improvements with milnacipran versus placebo in core
symptom domains, such as physical function, fatigue, and
cognitive dysfunction. The 6-month study involving 888
FM patients randomized to placebo, 100 mg/day or
200 mg/day of milnacipran was the lead-in to this
6-month extension study [31]. The objectives of this long-
term extension study were: 1) to determine whether the
improvements in pain and other FM symptoms that were
achieved at 6 months could be sustained through 1 year;
2) to further evaluate the efficacy of milnacipran in patients
who were switched from placebo during the lead-in study
to milnacipran in the extension study; and 3) to confirm the




This 6-month, randomized, multicenter, double-blind,
extension study was conducted at 51 U.S. centers from
May 20, 2004 to January 13, 2006. Patients completing
the 6-month lead-in study [31] in which they received
double-blind treatment with milnacipran 100 mg/day
(n = 224), milnacipran 200 mg/day (n = 441), or placebo
(n = 223), were eligible for enrollment. Of the 512 patients
completing the 6-month lead-in study (placebo, n = 145;
milnacipran 100 mg/day, n = 128; milnacipran 200 mg/
day, n = 239), 449 (87.7%) patients elected to continue
into this extension study. All participants in the present
study received milnacipran 100 mg/day (50 mg twice daily
[BID]) or 200 mg/day (100 mg BID) for a total of 28 weeks
(2-week dose-escalation period, 26-week stable-dose
period). The nature of the blinding was such that patients
were not informed of their treatment assignments during
the 6 months of the lead-in study. During the 6-month
extension period (this study), patients were informed that
they would receive milnacipran but remained blinded to the
dose they would receive.
Patients initially randomized to the milnacipran 200 mg/
day group in the lead-in study underwent a sham dose
escalation (i.e., no change in dosing) prior to stable-dose
maintenance at 200 mg/day (n = 209); those patients pre-
viously in the 100 mg/day group were re-randomized at a
1:4 ratio to continue at 100 mg/day (n = 19) or to escalate
to 200 mg/day (n = 92) for the extension study. Patients
initially randomized to the placebo group in the lead-in
study were re-randomized at a 1:4 ratio and escalated to
100 mg/day (n = 29) or 200 mg/day (n = 100) for the
extension study (Figure 1).
Participants
Patients 18–71 years of age with a diagnosis of FM, as
defined by the 1990 ACR [5], met all of the entry criteria for
the lead-in study, including: willingness to withdraw from
all centrally acting therapies commonly used for FM
(including antidepressants, sedative-hypnotic agents,
anticonvulsants, muscle relaxants, and mood stabilizers);
and for females of childbearing potential, a negative urine
pregnancy test prior to randomization and use of an
approved form of contraception. Patients with the follow-
ing criteria were excluded from the lead-in and the exten-
sion studies: severe psychiatric illness (assessed by the
Mini International Neuropsychiatric Interview [MINI] [32] in
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the lead-in study and by self-report or investigator judg-
ment in the extension study), including current major
depressive episode; significant risk for suicide (assessed
by investigator judgment); abuse of alcohol, benzodiaz-
epines, or other drugs (assessed by drug screening in the
lead-in study and repeated in the extension study at the
discretion of the investigator); any history of behavior that
would prohibit compliance for the duration of the study;
active cardiovascular, pulmonary, hepatic, renal, gas-
trointestinal, endocrine, or autoimmune disease; current
systemic infection; active cancer (except basal cell carci-
noma); pregnancy or breastfeeding; and genitourinary dis-
orders. Clinical investigator meetings were conducted to
uniformly train all interviewers (experienced psychiatrists,
psychologists, or other clinically trained professionals) in
the administration of the MINI.
Permissible concomitant therapies included NSAIDs;
herbal-based therapies except S-adenosylmethionine and
St John’s Wort; stable doses of corticosteroids equivalent
to 10 mg/day prednisone; 60 mg/day hydrocodone
(administered and analyzed as analgesic rescue therapy
and not allowed during the 48 hours prior to study visits);
zolpidem (Ambien), chloral hydrate, or over-the-counter
sleep remedies for insomnia; and the lowest possible
effective dose of the 5-HT1B/1D agonist rizatriptan (Maxalt)
to treat migraine headaches. Nonpermissible concomitant
medications were benzodiazepines, centrally acting anal-
gesics, anesthetic patches, antidepressants, and digoxin.
The study was approved by the Institutional Review Board
at each study center and was conducted in accordance
with the Guidelines for Good Clinical Practice [33]. All
patients gave written, informed consent.
Efficacy and Safety Outcome Measures
Consistent with the originally planned primary efficacy
parameters used in the lead-in study, the efficacy param-
eters included: patient-reported pain recalled over the
past 24 hours or past 7 days based on a 0–100 paper
visual analog scale (VAS) with anchors of “no pain” and
“worst possible pain”; the Patient Global Impression of
Change (PGIC) where patients rated their impression
of overall change in their FM since entering the extension
study using a 7-point scale (1 = “very much improved,”
7 = “very much worse”); and Fibromyalgia Impact Ques-
tionnaire (FIQ) total score and Physical Function subscale
score [34]. Additional efficacy measures were the Beck
Depression Inventory (BDI) [35], the Medical Outcome
Study (MOS)-Sleep Problems Index [36,37], Patient
Global Disease Status (PGDS), the Multidimensional
Fatigue Inventory (MFI) [38], and the Multiple Ability Self-
Report Questionnaire (MASQ) [39].
Baseline safety measurements were the last observed
value prior to the first dose of the double-blind study
medication in the lead-in study. Information on concomi-
tant medications and adverse events (AEs) was collected
Figure 1 Study design and patient disposition.
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at extension study weeks 1, 2, 8, 14, 20, and 28. Vital
signs were measured at extension study weeks 2, 8, 14,
20, and 28. Baseline efficacy measurements for the
lead-in study were the last assessments obtained prior to
randomization; baseline efficacy measurements for the
extension study were taken at the first extension study
visit (week 0, i.e., week 27 of the lead-in study). Efficacy
assessments were collected at extension study weeks 0,
8, 14, 20, and 28. BDI was assessed at extension study
weeks 0, 14, and 28. Patients who discontinued the study
prior to week 28 completed end-of-study assessments
at their last visit.
Tolerability and safety evaluations were based on vital
signs and spontaneously reported AEs recorded at study
visits. Both treatment-emergent AEs (TEAEs) as well as
newly-emergent AEs (NEAEs) were analyzed. TEAEs were
defined as AEs reported during the lead-in study (lead-in
study TEAEs) or extension study (extension-study TEAEs)
that either occurred after the first dose of medication in the
lead-in study (i.e., week 0) or increased in severity after
week 0. NEAEs were defined as the subset of TEAEs
reported during the extension study that were not present
prior to (or worsened after) the first dose of extension
study medication. Blood and urine samples for hematol-
ogy and clinical chemistry assessments were obtained at
weeks 14 and 28 (end of study) or upon study termination.
AEs were coded using Medical Dictionary for Regulatory
Activities (MedDRA; Maintenance and Support Services
Organization, Chantilly, VA) Version 8.1.
Statistical Analyses
All efficacy analyses were based on the intent-to-treat
population. Descriptive statistics (number of patients,
mean, standard error of the mean) and 95% confidence
intervals (95% CIs) were presented by the sequence of
treatment received in the lead-in study and the current
study. Analyses of VAS pain recall, FIQ, and PGIC scores
were based on patients with assessments at each study
visit where patient’s early termination assessment (if appli-
cable) was assigned to the next study visit, and included
changes from lead-in study and extension study baseline
values. Analyses of other efficacy parameters were based
on lead-in study baseline and end-of-study values, which
included week 28 (55 weeks of total treatment) assess-
ments from patients who completed treatment, as well as
assessments from patients who discontinued the study
early.
Results
Patient Demographics and Disposition
A total of 449 of the 512 patients (87.7%) who completed
the lead-in study [31] enrolled in this 6-month extension
study (Figure 1). There were no clinically relevant differ-
ences in demographic and baseline characteristics
between treatment groups (Table 1). The mean age of all
patients was 49.7 years, and most patients were female
(96.9%) and white (93.8%). The mean duration of FM was
5.3 years, and the mean lead-in study baseline paper VAS
24-hour recall pain scores (i.e., pain scores prior to ran-
domization in the lead-in study) could be described as
severe (73 out of 100) [40,41].
A total of 301 (67.0%) randomized patients completed the
28-week extension study (Figure 1). Of the randomized
patients, 17.8% discontinued due to AEs, 5.8% due to
withdrawal of consent, and 5.3% due to therapeutic
failure. The percentages of patients who discontinued
from the study because of AEs were slightly higher for
patients who switched from placebo to milnacipran or
from milnacipran 100 to 200 mg/day than for those who
remained at a fixed dose of milnacipran throughout both
studies. Rates of discontinuation were lowest for patients
with long-term exposure to milnacipran (i.e., continuation
of milnacipran at the same dose in the lead-in and exten-
sion studies [100 or 200 mg/day for 12 months]). Among
patients receiving milnacipran 200 mg/day in both the
lead-in and extension studies (n = 209), 141 (67.5%) com-
pleted the extension study and thus had 12 months of
continuous exposure to the highest dose used in these
studies. Among extension study patients who received
milnacipran 100 mg/day in the lead-in study (n = 111) and
were randomized to either 100 or 200 mg/day in the
extension study, a total of 76 (68.5%) patients completed
an additional 6 months, representing another group of
patients who received a total of 12 months of continuous
treatment with milnacipran. Overall, study drug compli-
ance (i.e., percentage of study drug capsules taken rela-
tive to the number prescribed) was 92%.
It should be pointed out that due to the randomization
ratios in the lead-in (1:1:2, placebo: milnacipran 100 mg/
day: milnacipran 200 mg/day) and extension studies (1:4,
milnacipran 100 mg/day: milnacipran 200 mg/day), rela-
tively few patients were treated with milnacipran 100 mg/
day in the extension study. Only 19 patients were
randomized to receive milnacipran 100 mg/day for the
entire 1-year treatment period, while 29 patients were
re-randomized from placebo to the 100 mg/day dose
(Figure 1). Therefore, the most robust information comes
from the patients treated with milnacipran 200 mg/day in
the extension study. The limited data for patients treated
with 100 mg/day in the extension study are summarized in
Tables 2 and 3.
Efficacy Outcomes
At the end of 1 year, patients treated with milnacipran
showed a marked improvement in pain, regardless of
whether they were maintained on milnacipran for the entire
1-year period or re-randomized from placebo to milnacip-
ran for the extension study. Patients maintained on mil-
nacipran 200 mg/day for 1 year had a mean decrease
from lead-in study baseline in 7-day recall pain scores of
-35.1 points (95% CI -39.9 to -30.4) (Figure 2A), while
patients re-randomized from placebo to milnacipran
200 mg/day had a mean decrease of -35.8 points (95%
CI -42.6 to -29.0) (Figure 2B). Respectively, these results
represent 46.7% and 47.2% improvements in pain. Similar
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Durability of Milnacipran Response for Fibromyalgia
results were observed in the 24-hour recall pain scores
(Table 3). For those patients maintained on milnacipran
200 mg/day for 1 year, improvements in pain (7-day recall
pain scores) at the end of the lead-in study (-32.5 points,
95% CI -36.7 to -28.3) were approximately the same as
improvements observed at the end of the extension study
(-35.1, 95% CI -39.9 to -30.4) (Figure 2A). These results
indicate that the pain improvements obtained in the first 6
months during the lead-in study were maintained during
the second 6 months of the extension study.
For patients re-randomized from placebo to milnacipran
200 mg/day, a decrease from extension study baseline in
7-day recall pain scores (-12.4 points) was evident by the
first assessment (week 8 of the extension study), represent-
ing a 22.8% improvement in pain. This improvement was
maintained at each of the visits in the extension study, with
mean changes from extension study baseline in 7-day
recall pain scores ranging from -11.0 to -14.1 points.
These results represent additional improvements in pain
over those observed during placebo treatment in the
lead-in study.
Similar to improvements seen in patients re-randomized
from placebo to milnacipran 200 mg/day, additional
improvements in pain perception during the extension
study were found in patients re-randomized from milnacip-
ran 100 mg/day to 200 mg/day. At week 28 in this group,
the mean change from extension-study baseline in 7-day
recall pain score was -2.8 points, representing an addi-
tional 7.1% improvement in pain (Figure 2). Similar
improvements from extension study baseline to week 28 in
24-hour recall pain were noted (data on file). Additionally, of
the 92 patients re-randomized from milnacipran 100 mg/
day to 200 mg/day, 36 were classified as pain nonre-
sponders at the end of the lead-in study (i.e., those patients
who did not achieve 30% improvement from baseline in
24-hour recall pain VAS scores). Of these lead-in study
nonresponders, 45.7% (16 of 35) reported a 30%
improvement in pain from extension study baseline at the
first visit following re-randomization to the higher dose
of milnacipran. At the final visit of the extension study,
39.1% (9 of 23) of patients reported a 30% improvement
in pain from extension study baseline, indicating that some
patients benefited from the higher milnacipran dose.
The primary outcome of the lead-in study was a
2-measure composite responder analysis that required
individual patients to achieve a simultaneous improvement
of 30% from baseline in 24-hour recall pain VAS scores
based on an electronic diary and a PGIC score of 1 (“very
much improved” or 2 (“much improved”). In the lead-in
study, there were 104 patients who were randomized to
milnacipran 200 mg/day who met this rigorous response
criterion at the end of the week 15 landmark visit and
subsequently entered this extension study. The pain data
for this cohort are shown in Figure 3, illustrating the
durable pain relief throughout the full year of treatment
experienced by this group.
In addition to the pain improvements described above,
patients demonstrated similar responses in other domains
Figure 2 Treatment effect of milnacipran 200 mg/day on 7-day recall pain scores for 1 year. Mean 7-day
recall pain scores in (A) patients re-randomized from milnacipran 100 mg/day to 200 mg/day or maintained
on milnacipran 200 mg/day, and (B) patients re-randomized from placebo to milnacipran 200 mg/day. Values
represent observed cases at each study visit. 100 to 200 = milnacipran 100 mg/day to milnacipran 200 mg/
day; 200 to 200 = milnacipran 200 mg/day to milnacipran 200 mg/day; PBO to 200 = placebo to milnacipran
200 mg/day; 95% CI = 95% confidence interval.
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important for fibromyalgia patients. Patients maintained on
milnacipran for 1 year or re-randomized from placebo to
milnacipran also showed marked and generally compa-
rable improvements in FIQ total scores relative to the
baseline of the lead-in study. In patients receiving mil-
nacipran 200 mg/day for 1 year, improvements in FIQ total
scores during the lead-in study were maintained for an
additional 6 months. Similar improvements from lead-in
study baseline were seen at end of the lead-in study
(-25.4, 95% CI -28.6 to -22.3) and at week 28 of the
extension study (-26.0, 95% CI -29.5 to -22.5)
(Figure 4A).
In patients re-randomized from placebo to milnacipran
200 mg/day, improvements in FIQ total score were
observed at all visits and were similar to improvements
seen in patients receiving continuous milnacipran
treatment (Figure 4B). Patients treated with milnacipran
100 mg/day in the lead-in study and subsequently
re-randomized to milnacipran 200 mg/day in the exten-
sion study showed further improvements in FIQ total score
at all extension study visits (Figure 4A).
In the lead-in study, significant differences favoring mil-
nacipran over placebo were observed for PGIC [31].
During the extension study, patients in all milnacipran
treatment groups continued to show improvement in
PGIC scores relative to entry into the extension study
(Table 4). At week 28, the mean PGIC scores were the
same for patients receiving 1 year of milnacipran 200 mg/
day (2.2, 95% CI 2.0–2.4) and those re-randomized from
placebo to milnacipran 200 mg/day (2.2, 95% CI 1.9–2.5).
Of the patients re-randomized from milnacipran 100 mg/
day to 200 mg/day (n = 92), 40 were classified as PGIC
nonresponders at the end of the lead-in study (i.e., those
patients who achieved a PGIC score >2). Among PGIC
nonresponders to milnacipran 100 mg/day during the
lead-in study, 12/25 (48.0%) were responders at the end
of the extension study (i.e., rated themselves as “much
improved” or “very much improved” on the PGIC).
Finally, patients treated with milnacipran showed improve-
ment at the end of the extension study (relative lead-in
study baseline) in other parameters important in FM
(Table 3).
Safety and Tolerability
Milnacipran was well tolerated at doses of 100 and
200 mg/day for up to 1 year. The overall incidence of
TEAEs during the extension study was 77.1% and 78.6%
among the milnacipran 100 mg/day and 200 mg/day
groups, respectively (Table 5). The most commonly
reported TEAE in the extension study was nausea (mil-
nacipran 100 mg/day, 22.9%; 200 mg/day, 23.9%). Other
TEAEs reported in at least 5% of total patients were sinusi-
tis, headache, constipation, hypertension, hyperhidrosis,
and dizziness.
The overall incidence of NEAEs was 68.8% and 74.3% for
milnacipran 100 mg/day and 200 mg/day, respectively
(Table 5). The overall incidence of NEAEs was similar
among patients re-randomized from placebo to milnacip-
ran 100 mg/day or 200 mg/day and those maintained on
milnacipran 200 mg/day. However, individual NEAEs such
as nausea, headache, hyperhidrosis, and constipation
were more common in patients re-randomized from
placebo to milnacipran 200 mg/day than in those continu-
ing on milnacipran. Patients re-randomized from milnacip-
ran 100 mg/day to 200 mg/day had a slightly greater
incidence of NEAEs compared with those re-randomized
from placebo to milnacipran 200 mg/day or those main-
tained on 200 mg/day. The incidence of NEAEs occurring
in the extension study was similar to that of TEAEs, with
the exception of nausea, which occurred at a lower rate as
an NEAE (milnacipran 100 mg/day, 18.8%; 200 mg/day,
17.5%).
Figure 3 One year pain relief in milnacipran
200 mg/day-treated patients who met 2-measure
composite responder criteria at week 15 of lead-in
study and continued in extension study. Values rep-
resent reported percent pain (24-hour recall score)
relative to the lead-in study baseline using last
observation carried forward. Pain data from the
lead-in study were collected using an electronic
visual analog scale (VAS) measure and data from the
extension study were recorded using a paper VAS
measure. Data were collected from responders at
week 15 (primary endpoint) of the lead-in study who
received milnacipran 200 mg/day during both the
lead-in and extension studies (n = 104). In the
lead-in study, 2-measure composite responders
were defined as patients reporting 30% reduction
in pain scores and a rating of “much improved” or
“very much improved” on the Patient Global Impres-
sion of Change.
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The profile of NEAEs occurring in the extension study was
similar to that of TEAEs in the 27-week lead-in study
(Figure 5). Prolonged exposure to milnacipran did not
result in any new safety concerns or findings. No new AEs
of concern emerged during the extension study that had
not already been reported during the lead-in study. The
most commonly reported AEs during the lead-in study
(i.e., nausea, headache, and constipation) occurred with
lower frequency during the extension study. The only two
AEs with a higher incidence in the extension study than in
the lead-in study were sinusitis (lead-in study, 6.5%;
extension study, 9.1%) and hypertension (lead-in study,
4.5%; extension study, 6.6%). AEs resulted in premature
discontinuation in 16.7% of milnacipran 100 mg/day
patients and 16.0% of milnacipran 200 mg/day patients.
The only AE resulting in premature discontinuation of
greater than 2% of patients was nausea (100 mg/day,
6.3%; 200 mg/day, 4.7%). Serious AEs were reported in
16 of 449 patients (3.6%) during the 6-month extension
study period, with five events (two patients with chest
pain, one patient with heart rate increased and heart rate
irregular, and one patient with migraine) judged as possibly
or probably related to study medication. There were no
deaths reported during the study. There were no clinically
relevant mean changes from baseline for any of the labo-
ratory parameters tested.
Some patients in the extension study experienced
changes in supine heart rate, systolic blood pressure
(SBP), and diastolic blood pressure (DBP) (Table 6). As
expected, patients who were re-randomized from placebo
to milnacipran had greater increases in heart rate and
blood pressure during the extension study as compared
with the lead-in study. These increases were similar to the
mean changes observed in the milnacipran pivotal trials
[29,31]. In patients receiving milnacipran for 1 year, mean
changes in vital signs during the lead-in study were gen-
erally similar to changes observed at the end of the exten-
sion study. These results suggest that for patients with
continuous milnacipran treatment, vital sign increases
mostly occurred during the lead-in study. Mean changes
in supine SBP and DBP in patients receiving milnacipran
100 mg/day group for 1 year were slightly higher during
the extension study than in the lead-in study; however, the
size of this treatment group was very small (n = 19). For
patients maintained on milnacipran 200 mg/day for 1 year,
mean supine DBP was lower at the end of the extension
study than at the end of the lead-in study. Similar results
were observed in mean supine DBP and heart rate in
patients who were escalated from milnacipran 100 mg/
day to 200 mg/day.
Potentially clinically significant (PCS) increases in supine
heart rate (120 bpm with an increase of 20 bpm from
baseline) and SBP (180 mm Hg with an increase of
20 mm Hg from baseline) were infrequent at both
dosages of milnacipran (<1%). The incidence of PCS
changes in supine SBP or heart rate did not increase with
long-term milnacipran treatment. In patients maintained
on milnacipran 100 mg/day in both studies (n = 19), PCS
Figure 4 Treatment effect of milnacipran 200 mg/day on Fibromyalgia Impact Questionnaire (FIQ) total
scores for 1 year. Mean FIQ total scores in (A) patients re-randomized from milnacipran 100 mg/day to
200 mg/day or maintained on milnacipran 200 mg/day, and (B) patients re-randomized from placebo to
milnacipran 200 mg/day. Values represent observed cases at each study visit. 100 to 200 = milnacipran
100 mg/day to milnacipran 200 mg/day; 200 to 200 = milnacipran 200 mg/day to milnacipran 200 mg/day;
PBO to 200 = placebo to milnacipran 200 mg/day; 95% CI = 95% confidence interval.
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increases in supine DBP (110 mm Hg with an increase
of 15 mm Hg from baseline) occurred in 5.6% of
patients. In patients receiving milnacipran 200 mg/day for
1 year, PCS increases in supine DBP occurred in 1.5% of
patients.
A more clinically relevant measure of the effect on blood
pressure may be the incidence of sustained hypertension.
Sustained increases in supine DBP (i.e., 90 mm Hg and
an increase of 10 mm Hg from baseline on three con-
secutive visits) occurred in 3.2% of patients receiving mil-
nacipran 200 mg/day. Sustained increases in supine SBP
values (i.e., 140 mm Hg and an increase of 20 mm Hg
from baseline on three consecutive visits) occurred in less
than 1% of patients receiving milnacipran 200 mg/day. No
sustained increases in supine DBP or SBP were observed
in patients treated with milnacipran 100 mg/day, although
this group was too small to allow meaningful conclusions.
The mean baseline body mass index (BMI) was 30.8 in the
extension study, indicating that many of the patients were
either overweight or obese (Table 1). Depending on the
treatment received during the lead-in study, patients could
have been exposed to milnacipran for 6 or 12 months. In
those patients treated with milnacipran 200 mg/day for 12
months, mean weight changes were -3.1 lbs at the end of
lead-in study (n = 209) and -1.4 lbs at the end of exten-
sion study (n = 141). Similarly, patients treated with mil-
nacipran 100 mg/day for 6 months and 200 mg/day for 6
months demonstrated mean weight changes of -3.1 lbs
at the end of lead-in study (n = 92) and -2.3 lbs at the end
of extension study (n = 61). In patients re-randomized
from placebo to milnacipran 200 mg/day, mean weight
changes were +0.1 lbs at the end of lead-in study
(n = 100) and -1.4 lbs at the end of extension study
(n = 65).
Discussion
The current study demonstrates that milnacipran is effec-
tive and well tolerated during continuous long-term treat-
ment for 1 year in FM patients. Data presented here
support and extend the findings of a 6-month double-
blind, placebo-controlled lead-in trial of milnacipran in the
treatment of FM [31]. Improvements in pain, global status,
physical function, and other FM-associated symptoms
that were observed after 6 months of treatment in the
placebo-controlled lead-in study were maintained for an
additional 6 months with continued milnacipran treatment.
Patients who received continuous treatment with mil-
nacipran 100 or 200 mg/day demonstrated persistent effi-
cacy over 1 year, with an improvement of 41% and 47%,
respectively, from lead-in study baseline in mean 7-day
recall pain scores at week 28. These changes represent
clinically meaningful improvements in pain (30% change
from baseline [42]), as well as a shift from severe pain
scores before treatment (mean pain scores >70) to mod-
erate pain scores after 6 to 12 months of milnacipran













































































































































































































































































































































































































































































































































































































































































Durability of Milnacipran Response for Fibromyalgia
In patients maintained on milnacipran 100 or 200 mg/day
for 12 months, the final observed 7-day recall pain scores
remained within 2% of extension study baseline scores. In
patients re-randomized from milnacipran 100 mg/day to
200 mg/day, the final observed weekly pain scores repre-
sented an additional 7.1% improvement from extension
study baseline. Furthermore, patients responding to mil-
nacipran treatment in the lead-in study showed durable
pain relief for at least 1 year. This trial also included efficacy
measures assessing the multiple symptoms associated
with FM, which included fatigue (MFI), cognitive dysfunc-
tion (MASQ), decreased functioning (FIQ), and sleep dis-
turbances (MOS-Sleep Problems Indices). Analyses of
these data demonstrated that after 1 year of milnacipran
treatment, patients showed improvements in fatigue,
functioning, and no worsening in sleep parameters.
This extension trial also demonstrated that patients
switched from milnacipran 100–200 mg/day had further
improvements in pain, PGIC, and FIQ. Approximately
40–50% of milnacipran 100 mg/day patients classified as
pain or PGIC nonresponders at the end of the lead-in
study became responders when switched to milnacipran
200 mg/day in the extension study. These results suggest
that some patients may achieve additional benefits from
the higher dose of milnacipran. Patients switched from
placebo to milnacipran 200 mg/day improved in pain, FIQ,
and PGIC scores, which is consistent with findings from
previous milnacipran clinical trials that showed improve-
ments in these measures in milnacipran-treated patients
compared with placebo [29–31]. In these patients,
improvements in pain from lead-in study baseline were
similar to those found in patients who were maintained on
continuous milnacipran treatment. Smaller changes in
pain and FIQ scores were observed in patients
re-randomized from placebo to milnacipran 100 mg/day
compared with other treatment arms, but the size of this
group was very small (n = 29) and included placebo
responders from the lead-in study.
Findings from the extension study demonstrate that the
majority of patients (88%) completing the lead-in study
elected to enroll in the extension study, and more than half
of these patients (67%) completed the additional 6
months of dose-blinded monotherapy. Additionally, 217 of
the 320 patients continuing on milnacipran in the exten-
sion study completed the study and thus were exposed to
1 year of continuous treatment. Of these 217 patients,
141 were on milnacipran 200 mg/day for the entire period.
Long-term treatment with milnacipran did not result in any
new safety concerns. In the 449 patients who chose to
enter this extension study, no new AEs of concern arose
during the extension trial that had not been observed in
the lead-in study. In these patients, milnacipran was gen-
erally well tolerated, with at least 90% of TEAEs rated as
mild to moderate in severity. Similar to other milnacipran
FM studies, the most commonly reported adverse event in
the extension study was nausea. Patients switched from
placebo or milnacipran 100 mg/day in the lead-in study to
200 mg/day in the extension study experienced slightly
higher incidences of AEs. Some patients in this study
experienced increases in heart rate and blood pressure;
Table 5 Treatment-emergent adverse events (TEAEs) and newly emergent adverse events (NEAEs) with











Any TEAE, n (%) 37 (77.1) 315 (78.6) 352 (78.4)
Nausea 11 (22.9) 96 (23.9) 107 (23.8)
Sinusitis 3 (6.3) 38 (9.5) 41 (9.1)
Headache 2 (4.2) 37 (9.2) 39 (8.7)
Constipation 4 (8.3) 29 (7.2) 33 (7.3)
Hypertension 2 (4.2) 30 (7.5) 32 (7.1)
Hyperhidrosis 4 (8.3) 27 (6.7) 31 (6.9)
Dizziness 3 (6.3) 23 (5.7) 26 (5.8)
Any NEAE, n (%) 33 (68.8) 298 (74.3) 331 (73.7)
Nausea 9 (18.8) 70 (17.5) 79 (17.6)
Sinusitis 3 (6.3) 33 (8.2) 36 (8.0)
Headache 2 (4.2) 30 (7.5) 32 (7.1)
Hyperhidrosis 4 (8.3) 25 (6.2) 29 (6.5)
Hypertension 2 (4.2) 27 (6.7) 29 (6.5)
Constipation 3 (6.3) 23 (5.7) 26 (5.8)
Dizziness 2 (4.2) 21 (5.2) 23 (5.1)
* Patients who received placebo (n = 29) or milnacipran 100 mg/day (n = 19) during the lead-in study.




regular monitoring of heart rate and blood pressure is
advisable in patients receiving milnacipran treatment.
Several limitations should be noted to the current study.
By study design, this was a continuation study of “com-
pleters” to the initial 6-month blinded, placebo-controlled
study. Patients were aware that they were taking the active
medication in this continuation trial, although they
remained blinded to the dose. The inclusion of placebo-
treated patients for another 6 months would have been
instructive but was not considered practical. The random-
ization scheme for both the lead-in, randomized trial, and
this extension report ensured that a large number of
patients were exposed to the 200 mg/day dose as it was
of interest to expand the pool of patients exposed to the
higher dose. However, this limited the number of patients
assigned to the 100 mg/day dose. Because of the limited
power to evaluate the efficacy and safety of the 100 mg/
day dose, no comments can be made as to the compa-
rable efficacy and tolerability of the two doses. However,
the slightly improved outcome when patients were
switched from the 100 to 200 mg/day dose without toler-
ability issues was important. In the United States,
milnacipran is approved at the 100 mg/day dose with
instructions that based on individual patient response, the
dose may be increased to 200 mg/day.
Figure 5 Adverse events in patients continuing mil-
nacipran treatment. Adverse events shown are
treatment-emergent adverse events (TEAEs) or
newly emergent adverse events (NEAEs) occurring
in 5% of patients in the lead-in or extension
studies, respectively. Lead-in study population:
patients receiving milnacipran 100 mg/day (N = 224)
or 200 mg/day (N = 441) for 6 months. Extension
study population: patients maintained on milnacip-
ran 100 mg/day (N = 19), 200 mg/day (N = 209), or
re-randomized from 100 to 200 mg/day (N = 92) for
















































































































































































































































































































































































































































































































































































































Durability of Milnacipran Response for Fibromyalgia
Patients with medical and psychiatric conditions were
excluded from the study. Additionally, patients discontin-
ued medications commonly used to treat FM as this was
a monotherapy design. Therefore, these findings may not
be generalizable to some FM patients seen in clinical
practice. Even though all patients, study site investigators,
and staff remained blinded to the dose of milnacipran
received in both the lead-in and extension studies, all
patients knew they were receiving some dose of milnacip-
ran during the extension study. Given the lack of placebo
comparator groups, limitations may exist in interpreting
the data. Furthermore, this study represents a select
group of patients. Of the 888 patients who were random-
ized in the lead-in study, 42% discontinued the study;
88% of the remaining and eligible patients chose to enroll
in the extension study. Thus, the extension study sample
represents the two following sets of patients: those who
tolerated milnacipran well and successfully adhered to
their medication for 6 months, and those who were dili-
gent and motivated enough to remain on placebo for 6
months.
In conclusion, these findings confirm the results of other
studies showing that milnacipran is well tolerated and
effective in the treatment of FM, improving both the pain
and multidimensional symptoms of FM. The effects of
milnacipran in the treatment of FM are durable and sus-
tained for at least 1 year in this patient population.
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